Chad M. Cohen - 06 Jul 2021 Form 4 Insider Report for Adaptive Biotechnologies Corp (ADPT)

Role: Chief Financial Officer
Signature: /s/ Chad Cohen by Eric Billings, Attorney-in-Fact
Issuer symbol: ADPT
Transactions as of: 06 Jul 2021
Net transactions value: -$642,619
Form type: 4
Filing time: 08 Jul 2021, 21:00:33 UTC
Previous filing: 10 Jun 2021
Next filing: 12 Aug 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ADPT	Common Stock	Options Exercise	$65,500	+10,000	+46%	$6.55	31,604	06 Jul 2021	Direct	F1
transaction	ADPT	Common Stock	Sale	$388,300	-10,000	-32%	$38.83^*	21,604	06 Jul 2021	Direct	F1, F2
transaction	ADPT	Common Stock	Options Exercise	$65,500	+10,000	+46%	$6.55	31,604	07 Jul 2021	Direct	F1
transaction	ADPT	Common Stock	Sale	$247,571	-6,486	-21%	$38.17^*	25,118	07 Jul 2021	Direct	F1, F3
transaction	ADPT	Common Stock	Sale	$137,749	-3,514	-14%	$39.20^*	21,604	07 Jul 2021	Direct	F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ADPT	Stock Option (Right to Buy)	Options Exercise	$0	-10,000	-9.1%	$0.000000	100,000	06 Jul 2021	Common Stock	10,000	$6.55	Direct	F1, F5
transaction	ADPT	Stock Option (Right to Buy)	Options Exercise	$0	-10,000	-10%	$0.000000	90,000	07 Jul 2021	Common Stock	10,000	$6.55	Direct	F1, F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020.
F2	The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $38.32 to 39.31, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F3	The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $37.775 to 38.735, inclusive.
F4	The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $38.875 to 39.42, inclusive.
F5	The options vested with respect to 1/4 of such shares on November 1, 2018, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.